News Image

Is NASDAQ:ETON suited for growth investing?

By Mill Chart

Last update: Mar 6, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ETON PHARMACEUTICALS INC (NASDAQ:ETON) is suited for growth investing. Investors should of course do their own research, but we spotted ETON PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

A Deep Dive into ETON PHARMACEUTICALS INC's Growth Metrics.

  • The Return on Equity(ROE) of ETON PHARMACEUTICALS INC is 13.2%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
  • With a track record of beating EPS estimates in the last 4 quarters, ETON PHARMACEUTICALS INC showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
  • The 1-year revenue growth of ETON PHARMACEUTICALS INC (74.16%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
  • The q2q revenue growth of 118.0% of ETON PHARMACEUTICALS INC highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
  • With a favorable trend in its operating margin over the past year, ETON PHARMACEUTICALS INC demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
  • ETON PHARMACEUTICALS INC has experienced notable growth in its free cash flow (FCF) over the past year, signaling improved cash generation and strong financial performance. This growth suggests the company's ability to generate excess cash for reinvestment or shareholder returns.
  • ETON PHARMACEUTICALS INC has shown positive momentum in its earnings per share (EPS) on a quarter-to-quarter (Q2Q) basis, with a 83.33% increase. This reflects the company's successful execution of its business strategies and its commitment to delivering improved financial results.
  • ETON PHARMACEUTICALS INC has seen a 42.86% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
  • In the most recent financial report, ETON PHARMACEUTICALS INC reported a 83.33% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
  • accelerating EPS growth for ETON PHARMACEUTICALS INC: the current Q2Q growth of 83.33% exceeds the previous year Q2Q growth of 50.0%.

What is the full fundamental picture of NASDAQ:ETON telling us.

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

ETON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 203 industry peers in the Pharmaceuticals industry. ETON has only an average score on both its financial health and profitability. ETON is not priced too expensively while it is growing strongly. Keep and eye on this one!

For an up to date full fundamental analysis you can check the fundamental report of ETON

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

ETON PHARMACEUTICALS INC

NASDAQ:ETON (5/24/2024, 7:25:10 PM)

3.58

-0.02 (-0.56%)

ETON News

News Image17 days ago - InvestorPlaceETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image17 days ago - BusinessInsiderETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the first quarter ...

News Image17 days ago - Eton PharmaceuticalsEton Pharmaceuticals Reports First Quarter 2024 Financial Results
News Image17 days ago - Eton PharmaceuticalsEton Pharmaceuticals Reports First Quarter 2024 Financial Results

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400•  Management to hold conference call today at 4:30pm ET

News Image25 days ago - Eton PharmaceuticalsEton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
News Image25 days ago - Eton PharmaceuticalsEton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...

News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak...

News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
News Imagea month ago - Eton PharmaceuticalsEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the

News Image2 months ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
News Image2 months ago - Eton PharmaceuticalsEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is...

ETON Links
Follow us for more